Italian Multicenter Study on Low‐Density Lipoprotein Apheresis Working Group 2009 Survey
Authors:
- Claudia StefanuttiCSClaudia Stefanutti
- the Italian Multicenter Study on Low‐Density Lipoprotein Apheresis Working GroupTGthe Italian Multicenter Study on Low‐Density Lipoprotein Apheresis Working Group
- 1 February 2013
- journal article
- clinical trial
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 17 (2) , 169-178
Abstract
We present results of the second survey of the Italian Multicenter Study on Low‐Density Lipoprotein Apheresis (IMSLDLa‐WG/2). The study involved 18 centers in 2009, treating 66 males and 35 females, mean age 47 ± 18 years. Mean age for initiation of drug treatment before low‐density lipoprotein apheresis (LDLa) was 31 ± 18 years, mean age to the first LDLa was 37 ± 20 years and average duration of treatment was 9 ± 6 years. The techniques used included direct adsorption of lipids, dextran sulfate cellulose adsorption, heparin‐mediated low‐density lipoprotein (LDL) precipitation, cascade filtration, and plasma exchange. The mean treated plasma/blood volumes/session were 3127 ± 518 mL and 8666 ± 1384 mL, respectively. The average plasma volume substituted was 3500 ± 300 mL. Lipid therapy before LDLa included ezetimibe, statins, ω‐3 fatty acids and fenofibrate. Baseline mean LDL cholesterol (LDLC) levels were 386 ± 223 mg/dL. The mean before/after apheresis LDLC level decreased by 67% from 250 ± 108 mg/dL (P = 0.05 vs. baseline) to 83 ± 37 mg/dL (P = 0.001 vs. before). Baseline mean Lipoprotein(a) [Lp(a)] level was 179 ± 136 mg/dL. Mean before/after apheresis Lp(a) level decreased by 71% from 133 ± 120 mg/dL (P = 0.05 vs. baseline) to 39 ± 44 mg/dL (P = 0.001 vs. before). Major and minor side effects occurred in 27 and 62 patients, respectively. Among patients with coronary artery disease (CAD), 62.3% had coronary angiography and 50.4% coronary revascularization before LDLa. Single vessel, double vessel and triple vessel CAD occurred in 19 (30.1%), 15 (23.8%) and 29 (46%) patients, respectively. Both CAD and extra‐CAD occurred in 41.5%, 39% had hypertension, 9.9% were smokers, 9.9% consumed alcohol and 42% were physically active. Ischemic cardiovascular events were not observed in any patient over 9 ± 6 years of treatment. Two centers have also treated 34 patients (females: 17/males 17; no. sessions: 36; average plasma volume treated: 3000 mL) for sudden hearing loss (SHL). Relief of symptoms was obtained, independently of the system used (HELP; cascade‐filtration).Keywords
This publication has 33 references indexed in Scilit:
- Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresisJournal of Clinical Lipidology, 2010
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Vascular Calcifications in Homozygote Familial HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Direct Adsorption of Low‐Density Lipoprotein by DALI‐LDL‐Apheresis: Results of a Prospective Long‐term Multicenter Follow‐up Covering 12 291 SessionsTherapeutic Apheresis and Dialysis, 2006
- Low‐density Lipoprotein Apheresis Therapy With a Direct Hemoperfusion Column: A Japanese Multicenter Clinical TrialTherapeutic Apheresis and Dialysis, 2006
- World apheresis registry: report of 2004 dataTherapeutic Apheresis and Dialysis, 2005
- Why some patients respond poorly to statins and how this might be remediedEuropean Heart Journal, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study groupTransfusion and Apheresis Science, 2001